CD antigens as drug target

Special drugs have been designed that identify and attack cells that have a particular type of CD antigens. These drugs are called monoclonal antibodies and they can attack only the type of cell that contains the specific target CD antigens. Monoclonal antibodies can also be tagged to drugs or radiation-emitting substances that add to the ability to kill cells that have the specific CD marker on their surface.

Examples of CD antigens targeted in lymphoma treatment

Rituxan (Rituximab) - a monoclonal antibody against CD20.
Zevalin (Ibritumomab Tiuxetan) - another antibody against CD20, tagged with a radiation emitting substance (Y90).
Bexxar (Tositumomab) - similar to Zevalin, only the radiation emitting substance is different (I131)
Gazyva (Obinutuzumab): targets CD20 antigen, used in initial treatment for small lymphocytic lymphoma/chronic lymphocytic leukemia.
Arzerra (Ofatumumab): targets CD 20 antigen, used in SLL/CLL.
Campath (Alemtuzumab): targets CD52 antigen in SLL/CLL and peripheral T-cell lymphomas.
Adcetris (Brentuximab vedotin): targets CD30 and is attached to a chemotherapy drug. Used in anaplastic large cell lymphoma.

CD antigens chart as drug target

Name Alias Function
CD2 T11, LFA-2, SRBC-R, Erythrocyte receptor, LFA-3R Adhesion between T-cells and other cell types and T-cell activation.
CD4 T4 T-cell activation, thymic differentiation and receptor for HIV
CD11a LFA-1, LFA1A, ITGAL Intracellular adhesion and costimulation.
CD20 B1, Bp35, MS4A1 B-cell activation and proliferation
CD27 T14, TNFRSF 7, CD27L receptor Costimulation of B- and T-cell activation
CD30 Ki-1, TNFRSF8 Regulates lymphocyte proliferation and cell death. Activation of NF-κB
CD40 TNFRSF5 Cell adhesion, cell proliferation, and signal transduction
CD47 IAP, MER6 Cell adhesion and signal transduction
CD52 CAMPATH-1, HE5, CDW52 Complement-mediated cell lysis and antibody-mediated cellular cytotoxicity
CD54 ICAM-1 Cell adhesion, lymphocyte activation, and migration
CD58 LFA-3 APC-T-cell adhesion. Killer target cell interaction.
CD62L L-selectin, LECAM-1, SELL Leukocyte rolling and homing on activated endothelium
CD70 Ki-24, CD27L, TNFSF7 Induces proliferation of costimulated T-cells. Enhances the generation of cytotoxic T-cells and contributes to T-cell activation.
CD79a MB1, IGA, Ig-alpha Subunit of B-cell antigen receptor.Signal transduction
CD80 B7, B7-1, BB1 Costimulation of T-cell activation and proliferation.
CD86 B70, B7-2, CD28LG2 Costimulation of T-cell activation and proliferation.
CD115 M-CSFR, c-fms, CSF1R Monocytic cell proliferation and differentiation
CD120b TNFR-II, TNFRSF1B, TNFR2 Receptor for TNF. Involved in cell differentiation, apoptosis and necrosis
CD127 IL-7R, IL7R Receptor for IL7
CD134 OX-40, TNFRSF4 T-cell activation, proliferation and differentiation, apoptosis and cell adhesion
CD137 TNFRSF9, 4-1BB, CDw137, ILA Costimulation of T-cell activation. Regulates T-cell-dependent immune responses.
CD137L 4-1BB, TNFRSF9, ILA Costimulation of T-cell activation
CD152 CTLA-4 T-cell inhibition
CD153 CD30L, TNFSF8 Binds to CD30 and induces proliferation of T-cells
CD154 CD40L, CD40 Ligand, gp39, TRAP Mediates B-cell proliferation, IgE production and is involved in immunoglobulin class switching
CD178 FasL, CD95L, FASLG, Fas Ligand T-cell mediated cytotoxicity
CD223 LAG-3 Involved in lymphocyte activation, negative regulation of T-cell activation
CD252 OX40L, gp34 Ligand for receptor TNFRSF4. Co-stimulates T-cell proliferation and cytokine production
CD253 TRAIL, Apo-2L, TL2, TNFSF10 Induces cell death by apoptosis
CD257 BLyS, BAFF, TALL-1, TNFSF13B Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity
CD258 LIGHT, HVEM-L, TNFRSF14 Stimulates T-cell proliferation, receptor for Herpes simplex virus
CD261 TRAIL-R1, DR4, TNFRSF10A Induces apoptosis, promotes activation of NFkB
CD262 TRAIL-R2, DR5, TNFRSF10B Activated by TNFSF10 / TRAIL and transduces apoptosis signal
CD264 DCR2, TRAIL-R4, TNFRSF10D Receptor for TRAIL, inhibits apoptosis
CD266 TWEAK-R, FGF-inducible 14, TNFRSF12A Receptor for TWEAK. Promotes angiogenesis and the proliferation of endothelial cells.
CD267 TACI, TNFR SF13B, TNFRSF13B Receptor for CD256 and CD257, mediates activation of the transcription factors NFAT, AP1, and NFkB.
CD268 BAFFR, TR13C,TNFRSF13C B-cell receptor for CD257. B-cell response
CD269 BCMA, TNFRSF13B, TNFRSF17 Receptor for CD256 and CD257, activates NFkB and JNK.
CD270 HveA, TR2, TNFRSF14 Receptor for CD258 and CD272.
CD272 BTLA Lymphocyte inhibitory receptor
CD273 B7DC, PD-L2, PDCD1L2 Stimulatory on dendritic cells, inhibits T-cell activation upon engaging the PD1 receptor.
CD274 B7-H1, PD-L1 Found on activated T cells, B cells, and myeloid cells, to modulate activation or inhibition
CD275 B7-H2, ICOSL, B7-RP1, GL50 Ligand for CD278. Costimulatory signal for T-cell proliferation and cytokine secretion, induces B-cell proliferation and differentiation
CD276 B7-H3 Enhances the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling
CD278 ICOS, AILIM Mediate cell-cell interactions, and effective help for antibody secretion by B-cells
CD279 PD1, SLEB2 Inhibitory cell surface receptor involved in T-cell tolerance
CD309 VEGFR2, KDR, FLK-1 Activation of this receptor by VEGF plays a role in angiogenesis, development, wound healing, cell proliferation, migration and differentiation
CD314 NKG2D, KLRK1 Receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells
CD339 Jagged-1, JAG1, JAGL1, hJ1 Ligand for multiple Notch receptors. Involved in the mediation of Notch signaling, cell fate determination in hematopoiesis and cardiovascular development
CD357 TNFRSF18, GITR Receptor for TNFSF18